We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The FORWARD PE ratio is the important one. These are transformational times for diagnostics companies.
Anyone posting about the historic PE is either thick or mischievous. Or both.
Sometimes you have to look at why investors DON’T own/like a company. Omega is widely seen as an antibody play, and many believe (incorrectly, but never mind...) that antigen is the way to go.
Omega will have both, this neutralising the risk of being stranded on the wrong side of the testing divide should one emerge.
This is a major plus point for investors seeking general exposure to the economics of testing.
MTA test -This test determines the concentration of COVID-19 (SARS-CoV-2) antigens in a saliva or swab extract sample to identify an individual with an infection. Mologic is currently evaluating a prototype in a number of healthcare settings and the results to date look promising. If this continues, then by the end of November, Omega would look to commence technical transfer of the test prior to commencing manufacturing.
Looks like a strong likelihood.
yep. put simply whatever omega can make they can sell. doesnt matter what test and for who they will sell them all. we can argue about the finer points of will it be november / december and will it be mologic's test or avacta's etc but conclusion is the same we will sell all our capacity.
The best of the testing plays.
Antigen testing will be the catalyst for new investors to commit their capital in the manner required for the shares to re-rate. Take a look on the “other” testing company boards; the common dismissal of Omega is that antibody tests have no value as they don’t tell you if you have the virus today.
The debate between the usefulness of antibody and antigen testing will continue. A company that has exposure to both is a winning proposition.
When Omega is understood to have antigen testing as well, then I expect to see the relative attractiveness of its shares re-appraised.
The RNS today is a good step towards that, and I am looking forward to the presentation later.